2026 ACC 科学声明:直接口服抗凝药在血栓事件一级与二级预防中的应用
该 ACC 科学声明系统梳理直接口服抗凝药(DOACs)在血栓事件一级与二级预防中的证据。内容涵盖房颤、静脉血栓栓塞症、特殊人群、围术期管理及卒中后抗栓策略等领域。文件强调 DOACs 仍有使用不足和剂量不当问题,旨在补充现有指南并支持个体化决策。
要点
- DOACs 已成为多数房颤和静脉血栓栓塞症患者的首选口服抗凝药。
- 高血栓风险及随机试验中代表性不足的人群中仍存在使用不足和剂量不当。
- 声明关注药物选择、出血风险评估、出血管理及成本等实际实施问题。
核心结论
- DOACs 已改变血栓栓塞性疾病的预防和治疗,较维生素 K 拮抗剂具有更好的药代动力学和安全性。
- 仍存在最佳实施方面的缺口,尤其在高血栓风险及随机试验代表性不足人群中。
研究设计与样本
- 该文件为美国心脏病学会(ACC)科学声明,采用基于证据的综述方法。
- 声明综合现有数据,补充现有临床实践指南并阐明不确定领域。
主要发现
- DOACs 在房颤和静脉血栓栓塞症中已成为多数患者的首选口服抗凝药。
- DOACs 仍存在使用不足和剂量不当的情况,尤其在高血栓风险及代表性不足人群中。
- 声明涵盖房颤、静脉血栓栓塞症、特殊人群、围术期及卒中后抗栓策略等领域。
关键数值与推荐
- 声明纳入慢性肾病、肝功能障碍、癌症、肥胖、衰弱、既往出血及瓣膜性心脏病等特殊人群的 DOAC 使用建议。
- 声明讨论左心耳封堵术后和导管消融后的抗栓策略。
- 声明涉及药物选择、用药时长、出血风险评估、抗凝相关出血管理及药物相互作用等条款。
临床怎么用
- 通过综合演变中的证据并阐明不确定领域,支持个体化、以患者为中心的决策。
- 关注药物选择、用药时长、出血风险评估、出血管理及药物相互作用等实施因素。
局限性
- 文件指出 DOACs 仍存在使用不足和剂量不当的问题。
- 部分人群在既往随机试验中代表性不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Direct oral anticoagulants (DOACs) have transformed the prevention and treatment of thromboembolic disease, offering predictable pharmacokinetics, fewer interactions, and improved safety compared with vitamin K antagonists. Over the past decade, DOACs have become the preferred oral anticoagulants for most patients with atrial fibrillation and venous thromboembolism; yet, important gaps remain in their optimal implementation across diverse clinical scenarios. Despite strong evidence supporting their efficacy and safety, DOACs continue to be underutilized and sometimes inappropriately dosed, particularly among patients at elevated thrombotic risk and in populations historically underrepresented in randomized trials. This American College of Cardiology Scientific Statement provides a comprehensive, evidence-based overview of established and emerging indications for DOAC therapy in primary and secondary prevention of thrombotic events. Key domains include anticoagulation in atrial fibrillation, acute and extended treatment of venous thromboembolism, management in special populations (including patients with chronic kidney disease, liver dysfunction, cancer, obesity, frailty, prior bleeding, and valvular heart disease), periprocedural anticoagulation, and antithrombotic strategies following stroke, left atrial appendage closure, and catheter ablation. The document also addresses practical considerations such as drug selection, dosing strategies, duration of therapy, bleeding risk assessment, management of anticoagulant-related bleeding, drug-drug interactions, adherence, and cost-related barriers to care. This statement is intended to complement existing clinical practice guidelines by synthesizing evolving data, clarifying areas of uncertainty, and supporting individualized, patient-centered decision making. By addressing both evidence and implementation challenges, this document aims to improve the appropriate and equitable use of DOACs across the spectrum of thrombotic disease.
引用
- Kumbhani, Armbruster, Cheng, et al. Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. 2026. PMID: 42377292. doi:10.1016/j.jacc.2026.05.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。